CDKN2A and astrocytoma (excluding glioblastoma): Furthermore, we provide possible future avenues to improve histomolecular prognostic assessment of IDH-mutant astrocytoma based on CNS WHO grade, global DNA methylation level, and CDKN2A homozygous deletion (Fig. 3).